ABLI.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 Jun 2024 @ 03:56):

Stats
Today's Volume	214 366
Average Volume	1.42M
Market Cap	185.28M
EPS	SEK-0.0172 ( 2024-05-23 )
Next earnings date	( SEK0 ) 2024-08-22
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-1.950
ATR14	SEK0.00100 (0.57%)

Volume Correlation

Long: -0.28 (neutral)

Short: 0.40 (neutral)

Signal:(49.111) Neutral

Abliva AB (publ) Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Abliva AB (publ) Correlation - Currency/Commodity

0.29
( neutral )

0.53
( weak )

0.00
( neutral )

0.08
( neutral )

-0.55
( weak negative )

Abliva AB (publ) Financials

Annual	2023
Revenue:	SEK137 000
Gross Profit:	SEK-35.66M (-26 031.39 %)
EPS:	SEK-0.0904

FY	2023
Revenue:	SEK137 000
Gross Profit:	SEK-35.66M (-26 031.39 %)
EPS:	SEK-0.0904

FY	2023
Revenue:	SEK0
Gross Profit:	SEK0 (0.00 %)
EPS:	SEK0

FY	2022
Revenue:	SEK31 000.00
Gross Profit:	SEK-84.91M (-273 887.10 %)
EPS:	SEK-0.110

Financial Reports:

No articles found.

Abliva AB (publ) Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Abliva AB (publ)

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.